Influenza A virus hemagglutinin (H1N1pdm09) (HA)

Influenza A virus hemagglutinin (HA) is the primary surface glycoprotein of the H1N1pdm09 virus, which emerged in 2009 to cause a global pandemic [1]. It functions as a class I fusion protein, playing a critical role in the viral life cycle by mediating the attachment of the virus to sialic acid receptors on host respiratory cells [2]. Following attachment, HA facilitates the fusion of the viral envelope with the host endosomal membrane, allowing the viral genome to enter the cytoplasm [2]. HA is the principal antigen targeted by the host adaptive immune system, and its globular head domain contains the major epitopes for neutralizing antibodies [1, 3]. Due to its essential role in infection, HA is the central component of both seasonal and pandemic influenza vaccines [3]. It is also a major target for the development of novel antivirals, including monoclonal antibodies like MEDI8852 and small-molecule fusion inhibitors like umifenovir [4, 5]. However, the high rate of mutation in the HA gene, known as antigenic drift, allows the virus to escape immune recognition and necessitates frequent updates to vaccine strains [1, 3]. Additionally, antigenic shift through reassortment can lead to the emergence of novel HA subtypes with pandemic potential [1]. Therapeutic challenges include the need for broadly neutralizing antibodies that target the more conserved stalk region of the protein [4]. Monitoring HA through hemagglutination inhibition assays remains the gold standard for assessing population immunity and vaccine efficacy [3].

Other names

H1 HApdm09 HAH1N1pdm09 HAHemagglutininpdm09 hemagglutinin antigenSwine-origin influenza hemagglutinin

Neutralization of viral entry by blocking receptor binding or preventing membrane fusion.